Real-life Treatment Paradigms Show Infliximab Is Cost-effective forManagement of Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1871-1878.e8

  Ung, Victoria ^a   Thanh, Nguyen Xuan ^b   Wong, Karen ^a   Kroeker, Karen I ^a   Lee, Thomas ^a   Wang, Haili ^a   Ohinmaa, Arto ^b   Jacobs, Philip ^b   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

Author keywords

Corticosteroid; Cost Utility Analysis; ICER; Inflammatory Bowel Disease; Proctocolectomy

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; DRUG DOSE INCREASE; FEMALE; HEALTH CARE ACCESS; HEALTH STATUS; HUMAN; MALE; PATIENT PREFERENCE; PHARMACEUTICAL CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT RESPONSE; TYPES OF STUDY; ULCERATIVE COLITIS; ALBERTA; COHORT ANALYSIS; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMICS; ONTARIO; TREATMENT OUTCOME;

ADULT; ALBERTA; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; ONTARIO; TREATMENT OUTCOME;

EID: 84908257299     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.03.012     Document Type: Article

References (43)

1. Fedorak R., Wong K., Bridges R. Canadian Digestive Health foundation public impact series: inflammatory bowel disease in Canada-incidence, prevalence and direct and indirect economic impact. Can J Gastroenterol 2010, 24:651-655.
2. Jess T., Riis L., Vind I., et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007, 13:481-489.
3. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
4. Feagan B.G., Reinisch W., Rutgeerts P., et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102:794-802.
5. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. NEngl J Med 2005, 353:2462-2476.
6. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260.
7. Loomes D.E., Teshima C., Jacobs P., et al. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol 2011, 25:497-502.
8. Waters H.C., Vanderpoel J.E., Nejadnik B., et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. JMed Econ 2012, 15:45-52.
9. Manson S.C., Brown R.E., Cerulli A., et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009, 103:975-994.
10. Berndtsson I.E., Carlsson E.K., Persson E.I., et al. Long-term adjustment to living with an ileal pouch-anal anastomosis. Dis Colon Rectum 2011, 54:193-199.
11. Sinclair L.G. Young adults with permanent ileostomies: experiences during the first 4 years after surgery. JWound Ostomy Continence Nurs 2009, 36:306-316.
12. Carlsson E., Bosaeus I., Nordgren S. What concerns subjects with inflammatory bowel disease and an ileostomy?. Scand J Gastroenterol 2003, 38:978-984.
13. Gies N., Kroeker K.I., Wong K., et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of asingle-centre cohort. Aliment Pharmacol Ther 2010, 32:522-528.
14. Oussalah A., Evesque L., Laharie D., et al. Amulticenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010, 105:2617-2625.
15. Schabert V.F., Watson C., Gandra S.R., et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. JMed Econ 2012, 15:264-275.
16. Punekar Y.S., Hawkins N. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis. Eur J Health Econ 2010, 11:67-76.
17. Tsai H.H., Punekar Y.S., Morris J., et al. Amodel of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008, 28:1230-1239.
18. Xie F., Blackhouse G., Assasi N., et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009, 7:20.
19. Dretzke J., Edlin R., Round J., et al. Asystematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011, 15:1-244.
20. CEDAC final recommendation and reasons for recommendation: infliximab (Remicade - Centocor Inc) indication-ulcerative colitis 2009, Canada: Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON.
21. Heikens J.T., de Vries J., van Laarhoven C.J. Quality of life, health related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review. Colorectal Dis 2012, 14:536-544.
22. Lix L.M., Graff L.A., Walker J.R., et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1575-1584.
23. Waljee A., Waljee J., Morris A.M., et al. Threefold increased riskof infertility: a meta-analysis of infertility after ileal pouchanal anastomosis in ulcerative colitis. Gut 2006, 55:1575-1580.
24. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
25. Reinisch W., Sandborn W.J., Rutgeerts P., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012, 18:201-211.
26. Su C., Salzberg B.A., Lewis J.D., et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97:2577-2584.
27. Keshavarzian A., Mayer L., Salzberg B., et al. Amulticenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol 2007, 3:381-390.
28. Teshima C.W., Thompson A., Dhanoa L., et al. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009, 23:348-352.
29. Gornet J.M., Couve S., Hassani Z., et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003, 18:175-181.
30. Rostholder E., Ahmed A., Cheifetz A.S., et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012, 35:562-567.
31. Ma C., Huang V., Fedorak D., et al. Outpatients with ulcerative colitis being treated with adalimuamb and infliximab have similar rates of loss of response. Can J Gastroenterol Hepatol 2014, 28:A141.
32. Arseneau K.O., Sultan S., Provenzale D.T., et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?. Clin Gastroenterol Hepatol 2006, 4:1135-1142.
33. Tursi A., Giorgetti G.M., Brandimarte G., et al. Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohn's disease. Inflamm Bowel Dis 2007, 13:1184-1186.
34. Hueting W.E., Buskens E., van der Tweel I., et al. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg 2005, 22:69-79.
35. Rajaratnam S.G., Eglinton T.W., Hider P., et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Colorectal Dis 2011, 26:1365-1374.
36. Jess T., Loftus E.V., Velayos F.S., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 2006, 130:1039-1046.
37. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ 2009, 338:b181.
38. Rocchi A., Menon D., Verma S., et al. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health 2008, 11:771-783.
39. Rocchi A., Miller E., Hopkins R.B., et al. Common Drug Review recommendations: an evidence base for expectations?. Pharmacoeconomics 2012, 30:229-246.
40. Ternouth AM, Chapman M, Modha R. An assessment of the variation in accepted ICERs by disease type: results from four HTAS (poster). Health Technology Assessment: A European Collaboration. ISPOR 13th Annual European Congress, Prague, Czech Republic. November 6-9, 2010.
41. Carter C.T., Leher H., Smith P., et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011, 17:385-392.
42. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
43. Rubenstein J.H., Chong R.Y., Cohen R.D. Infliximab decreases resource use among patients with Crohn's disease. JClin Gastroenterol 2002, 35:151-156.